Effects of avitriptan, a new 5 HT(1B/1D) receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 355, Issue 2, 1997, Pages 295-302

  Saxena, Pramod R ^a   De Vries, Peter ^a   Wang, Wei ^a   Heiligers, Jan P C ^a   Maassen VanDenBrink, Antoinette ^a   Bax, Willem A ^a   Yocca, Frank D ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antimigraine drugs; Arteriovenous anastomoses; Avitriptan; BMS 180048; Carotid artery; Human; Human coronary artery; Migraine; Pig; Sumatriptan

Indexed keywords

AVITRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN;

ANIMAL EXPERIMENT; ARTERIOVENOUS FISTULA; ARTICLE; CAROTID ARTERY FLOW; CONTROLLED STUDY; CORONARY ARTERY; DRUG SCREENING; EXPERIMENTAL MODEL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; NONHUMAN; NORMAL HUMAN; SWINE;

ANIMALS; ARTERIOVENOUS ANASTOMOSIS; BLOOD PRESSURE; CAROTID ARTERIES; CORONARY VESSELS; HEAD; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; INDOLES; MIGRAINE DISORDERS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SULFONAMIDES; SUMATRIPTAN; SWINE; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 0031012293     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004946     Document Type: Article

References (46)

1. Bax WA, Saxena PR (1993) Sumatriptan and ischaemic heart disease. Lancet 341:1420
2. Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D, Thijssen EJM. Bos E. Saxena PR (1993) 5-HT receptors mediating contractions of the isolated human coronary artery. Eur J Pharmacol 239:203-210
3. Beattie DT, Connor HE, Feniuk W, Humphrey PPA (1994) The pharmacology of sumatriptan. Rev Contemp Pharmacother 5:285-294
4. 1D receptor agonists sumatriptan and MK-462. Br J Pharmacol 116:38P
5. Chester AH, Martin GR, Bodelsson M, Arneklo-Nobin B, Tadjkarimi S, Tornebrandt K, Yacoub MH (1990) 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovasc Res 24:932-937
6. 1D antagonists. J Med Chem 37:2253-2257
7. 2 receptor activation. Eur J Pharmacol 161:91-94
8. De Lean A, Munson PJ, Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curves. Am J Physiol 235:E97-E102
9. 1D receptor antagonist. Br J Pharmacol 118:85-92
10. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 102:323-330
11. 1-like receptors. Br J Pharmacol 104:183-189
12. 1D-receptors involved? Naunyn-Schmiedeberg's Arch Pharmacol 345:509-515
13. Den Boer MO, Van Woerkens LJ, Somers JAE, Duncker DJ, Lachmann B, Saxena PR, Verdouw PD (1993) On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia. J Appl Physiol 75:782-789
14. 1A receptor agonist flesinoxan in the cat. J Cardiovasc Pharmacol 14:770-776
15. Feniuk W, Humphrey PPA, Perren MJ (1989) The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized does. Br J Pharmacol 96:83-90
16. Ferrari MD, Saxena PR (1993) Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 14:129-133
17. Goggins G, Mahle C, Yocca FD (1996) Constriction of pressurized guinea pig middle cerebral artery by BMS-180048 and naratriptan. Abstract, 3rd European Headache Conference, Sardinia, Italy, p 6b
18. Goldstein J, Ryan RE Jr, Elkind AH (1996) A double-blind trial of BMS-180048 at 75 mg, 150 mg and 200 mg in the acute treatment of migraine headaches. Abstract. 3rd European Headache Conference, Sardinia, Italy, p 2b
19. 1Dβ receptor subtype in human and bovine cerebral. Mol Pharmacol 44:242-246
20. 1D receptor subtypes. Trends Pharmacol Sci 17:103-105
21. Heyck H (1969) Pathogenesis of migraine. Res Clin Stud Headache 2:1-28
22. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157-203
23. 1-like receptor in dog isolated saphenous vein. Br J Pharmacol 94:1123-1132
24. Humphrey PPA, Apperley E, Feniuk W, Perren MJ (1990) A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR, Wallis DI, Wouters W, Bevan P (eds) Cardiovascular pharmacology of 5-hydroxytryptamine: prospective therapeutic applications. Kluwer academic publishers. Dordrecht, pp 416-131
25. Johnston BM, Saxena PR (1978) The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 63:541-549
26. 1Dβ receptors. Circulation 90:1141-1153
27. 1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 87:401-405
28. Martin GR, R Dixon (1995) Pre-clinical and clinical pharmacology of the novel antimigraine compound 311C90. Poster, American Association for the Study of Headache, Toronto
29. 1D binding sites. Eur J Pharmacol 163:133-136
30. Perren MJ, Feniuk W, Humphrey PPA (1989) The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia 9 [Suppl 9]:41-46
31. Ploeg RJ, Van Bockel JH, Langendijk PTH, Groenewegen M, Van der Woude FJ, Persijn GG, Thorogoed J, Hermans J (1992) Effect of preservation solution on results of cadaveric kidney transplantation. Lancet 340:129-137
32. Saxena PR (1990) Is there still a case for the shunt hypothesis in migraine? In: Sandler M, Collins GM (eds) Migraine: a spectrum of ideas. Oxford University Press, Oxford, pp 191-199
33. Saxena PR (1995) Cranial arteriovenous shunting: an in vivo animal model for migraine. In: Olesen J, Moskowitz MA (eds) Experimental headache models in animal and man. Lippincott-Raven Publishers, Philadelphia, pp 189-198
34. Saxena PR, DeVlaam-Schluter GM (1974) Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine Studies in an animal experimental model for migraine. Headache 13:142-163
35. Saxena PR, Ferrari MD (1992) From serotonin receptor classification to the antimigraine drug sumatriptan. Cephalalgia 12:187-196
36. 1D receptor agonists. Exp Opin Invest Drugs 5:581-593
37. Saxena PR, Tfelt-Hansen P (1993) Sumatriptan. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The headaches. Raven Press Ltd, New York, pp 329-341
38. Saxena PR, Verdouw PD (1982) Redistribution by 5-HT of carotid arterial blood at the expense of arteriovenous blood flow. J Physiol (Lond) 332:501-520
39. Saxena PR, Villalón CM (1990) Cardiovascular effects of serotonin agonists and antagonists. J Cardiovasc Pharmacol 15 [Suppl 7]:S17-S34
40. Saxena PR, Schamhardt HC, Forsyth RP, Loeve J (1980) Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comp Progr Biomed 12:63-84
41. 1-like receptors. Naunyn-Schmiedeberg's Arch Pharmacol 333:198-204
42. Schamhardt HC, Verdouw PD, Van Der Hoek TM, Saxena PR (1979) Regional myocardial perfusion and wall thickness and arteriovenous shunting after ergotamine administration to pigs with a fixed coronary stenosis. J Cardiovasc Pharmacol 1:673-686
43. 1D receptor antagonist. Br J Pharmacol 110:9P
44. Spierings ELH, Saxena PR (1980) Antimigraine drugs and cranial arteriovenous shunting in the cat. Neurology 30:696-701
45. The Subcutaneous Sumatriptan International Study Group (1991) Treatment of migraine with sumatriptan. N Engl J Med 325:316-321
46. 1D agonist. Cephalalgia 15 [Suppl 14]:174